Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Sep 28,2020
Slow-release dual agonist therapy can treat hyperglycemia and obesity
China has the largest number of diabetic patients in the world, followed by India and the United States. According to the latest statistics, my country currently has 116.4 million diabetic patients. One out of every four diabetic patients in the world comes from China, and this trend is expected to continue until 2045. Currently, itRead more
More
Slow-release dual agonist therapy can treat hyperglycemia and obesity
Sep 25,2020
Focus on CRISPR: Transforming fat cells, may "lying thin" come true?
The number of obesity and metabolic syndrome is increasing rapidly around the world and will cause high morbidity and mortality. The medical community has been focusing on the development of prevention and treatment strategies for obesity and its complications. In mammals, both brown adipose tissue (BAT) and white adipose tissue (WAT) can promote energy homeostasisRead more
More
Focus on CRISPR: Transforming fat cells, may "lying thin" come true?
Sep 24,2020
Conquering triple-negative breast cancer
According to the 2018 International Agency for Research on Cancer (IARC) survey data, the incidence of breast cancer in female cancers worldwide is 24.2%, ranking first among female cancers, of which 52.9% occur in developing countries. From the age of onset, the incidence of breast cancer gradually rises after the age of 20, reaching aRead more
More
Conquering triple-negative breast cancer
Sep 14,2020
Analysis on the progress of the consistency evaluation of generic drugs in 2020
After several years of development, the consistency evaluation of generic drugs has made some progress. As of August 2020, 600 companies across the country have actively participated in the evaluation, and a total of 533 varieties and 2,319 drugs have been accepted. With the continuous deepening of consistency evaluation, local development will face more fierceRead more
More
Sep 11,2020
R&D CRO List- 2020 China’s Top 20 CRO Companies
On September 10, 2020, the " 2020 China Pharmaceutical and Health Industry Development Conference and the 4th China Pharmaceutical R&D Innovation Summit (PDI)" announced the "2020 China Top 20 R&D CRO Companies".
More
R&D CRO List- 2020 China’s Top 20 CRO Companies
Aug 25,2020
Medicilon's Metabolite Identification Services
Metabolite identification (MetID) plays an important role in drug discovery and development process. During the lead optimization stage, early MetID study can help identify the metabolic "soft spots”, so medicinal chemists can make appropriate structure modification to improve the pharmacokinetic properties of the compounds. During the IND-enabling stage, the information obtained from cross-species metabolite profilingRead more
More
Medicilon's Metabolite Identification Services
Aug 07,2020
Can inhaled administration bring new dawn to the clinical treatment of COVID-19 patients?
Due to the portability of inhaled preparations and better patient compliance, inhalation administration has become the most commonly used mode of administration after oral administration, and more and more attention and approval have been paid to the inhalation administration route. For patients with lung disease, compared with other modes of administration, inhaled administration can achieveRead more
More
Can inhaled administration bring new dawn to the clinical treatment of COVID-19 patients?
Jul 28,2020
CRISPR on the cusp
CRISPR has made the limelight in the medical news in recent months and proved the milestone of clinical efficacy and safety. Accompanied by the research of unstable and uncontrollable gene mutation sites of CRISPR, CRISPR gene editing therapy has been pushed to the forefront. Discover At the end of the 1980s, Japanese scientists discovered suchRead more
More
CRISPR on the cusp
Jul 20,2020
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more
More
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
Jul 14,2020
Biological Experiment Technology Service Company
Shanghai Medicilon has extensive and extensive experience in molecular biology services, in vitro biology, cell biology services and structural biology. From the initial cDNA library construction to drug design, through protein purification, structure determination and analytical determination, we provide a complete set of biological technical services.
More
Biological Experiment Technology Service Company
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->